trigger watch lt
near-term trigger acip vote remov prevnar adult
recommend gene therapi data dmd rare diseas
opportun tanezumab pain safeti clariti biosimilar
launch updat although lower estim
continu expect acceler growth earli next decad
lower project continu anticip acceler growth longer-
term lower revenu ep
also lower revenu
ep continu project
acceler growth earli next decad due new pipelin contribut
fade gener pressur estim compound-annual-growth-rate revenue growth
ep new vs old vs consensu estim
risk us prevnar adult vaccin current model sale
continu us advisori committe immun practic committe
could vote remov routin adult recommend prevnar vaccin
februari june meet recal acip question
cost effect routin vaccin recommend due herd
benefit may vote remov state acip analysi
includ zero benefit serotyp coverag contradict data
indic benefitwhich thu chang cost effect math
believ difficult predict acip act current expect
remov recommend elimin think us prevnar sale could
hit approxim total rev/ep could reduc
respect even adult vaccin recommend
remov could ad back year assum prevnar
gene therapi duchenn muscular dystrophi dmd data repres
new rare diseas opportun plan present mini-
dystrophin gene therapi data possibl may head
dolsten said decemb see compani candid neck
neck two biotech sarepta solid state seen
encourag sign efficaci thu step dose order maxim
treatment benefit although consensu expect data first
lowest dose patient think possibl data recent higher
dose patient could also present result surprisingli compel
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
stock rate price target estim avail
remov due applic law and/or polici
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
would drive greater enthusiasm drug early-stag
pipelin particularli wake tafamadi surpris success
tanezumab partner long-term phase trial readout
come month yield safeti clariti recal novel drug pain
associ joint damag risk see jan report tanezumab safeti
issu persist detail
state jan call plan launch three oncolog
biosimilar us intend launch biosimilar three roch
drug us fda action date bherceptin
bavastin brituxan note ms roch analyst mark purcel
assum later launch due patent litig await updat
act financi advisor inc relat
agreement glaxosmithklin plc glaxo creat global consum
healthcar compani contribut consum healthcar
busi glaxo exist consum healthcar busi announc
decemb propos joint ventur subject approv glaxo
sharehold customari close condit includ regulatori
approv report inform provid herein intend
provid vote advic ii serv endors propos transact
iii result procur withhold revoc proxi
action secur holder agre pay fee
servic includ transact fee conting upon consumm
propos transact pleas refer note end report
new vs old vs consensu estim
consensu model pipelin contribut includ ibranc adjuv ramp
price
price
price
compani data thomson reuter morgan stanley research valuat methodolog risk associ price target referenc
research report pleas contact client support follow us/canada hong kong latin america
 london singapor sydney tokyo altern may
contact invest repres morgan stanley research broadway attent research manag new york ny usa
us major pharma includ
sg sale
 sale
short-term
a/p accru
total liabil
chang work
oper
invest
net chang debt
financ
net chang cash
